ADAR1 Capital Management, LLC has recently reported transactions increasing its stake in InMed Pharmaceuticals Inc. This move is significant as it highlights ADAR1's commitment to the pharmaceutical sector, potentially influencing market dynamics.
ADAR1 Capital Management, LLC is based in Austin, Texas, and operates as a private investment firm. The company is not publicly traded and focuses on managing investment funds. InMed Pharmaceuticals Inc., the issuer of the shares, is involved in pharmaceutical preparations and is listed under the ticker symbol INM.
The recent SEC filing, accession number 0001940272-26-000026, details two transactions where ADAR1 acquired a total of 1,087 common shares of InMed Pharmaceuticals on October 16 and October 19, 2026, at a price of $1.32 per share. Following these transactions, ADAR1 now holds a total of 956,580 shares in InMed.
This filing indicates that Daniel Schneeberger, the sole manager of ADAR1, is a significant owner of these shares, as the securities are owned directly by private investment funds managed by ADAR1. The filing also notes that both ADAR1 and Schneeberger disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.
The increased stake may impact various stakeholders, including investors and market analysts, as it suggests confidence in InMed's future prospects. Furthermore, it reflects ongoing trends in the pharmaceutical industry, where investment firms are actively seeking opportunities in innovative companies.
What happens next remains unclear as the filing does not specify any upcoming actions or further disclosures.